Cargando…

T195. PSYCHOTIC DISORDERS IN PATIENTS WHO USE SYNTHETIC CANNABINOIDS: CLINICAL CHARACTERISTICS AND PATIENT PROFILE

BACKGROUND: Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are the two principal ingredients of natural cannabis with counteracting functions. Synthetic cannabinoids (SCs) are much more potent than natural cannabis, since they act as a more potent full agonist at the cannabinoid subtype 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skriabin, Valentin, Vinnikova, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234651/ http://dx.doi.org/10.1093/schbul/sbaa029.755

Ejemplares similares

T241. INCIDENCE AND SOCIO-DEMOGRAPHIC/CLINICAL CHARACTERISTICS OF PSYCHOTIC DISORDERS IN INDIA, NIGERIA AND TRINIDAD: PRELIMINARY BASELINE FINDINGS FROM INTREPID II
por: Roberts, Tessa, et al.
Publicado: (2020)

T43. PREDNISOLONE VERSUS PLACEBO AS AUGMENTATION THERAPY IN PSYCHOTIC DISORDERS
por: Lyliana, Nasib, et al.
Publicado: (2020)

T123. RISK FACTORS FOR PSYCHOTIC DISORDERS WITHIN MIGRANT GROUPS IN CANADA
por: Anderson, Kelly, et al.
Publicado: (2020)

T56. RISKY DECISION-MAKING IMPAIRMENT IN EARLY-STAGE PSYCHOTIC BIPOLAR DISORDER
por: Chung Man Ng, Mary, et al.
Publicado: (2020)

T87. CHANGING RATES OF PAST-YEAR CANNABIS USE BY PEOPLE WITH A PSYCHOTIC DISORDER
por: Waterreus, Anna, et al.
Publicado: (2020)

T82. THE IMPACT OF SMOKING ON LIFE EXPECTANCY IN PSYCHOTIC DISORDERS, AN ELECTRONIC CASE REGISTER COHORT STUDY
por: Chesney, Edward, et al.
Publicado: (2020)

T140. PERSONALITY AND NEUROCOGNITIVE CORRELATES OF PSYCHOTIC-LIKE EXPERIENCES
por: Blain, Scott, et al.
Publicado: (2020)

T128. ATTACHMENT REPRESENTATIONS IN CHILDREN AT FAMILIAL HIGH RISK OF SEVERE MENTAL DISORDERS. ASSOCIATIONS WITH PSYCHOPATHOLOGY, LEVEL OF FUNCTIONING, AND PSYCHOTIC EXPERIENCES
por: Gregersen, Maja, et al.
Publicado: (2020)

T112. PTSD AS A MEDIATOR OF THE RELATIONSHIP BETWEEN TRAUMA AND PSYCHOTIC EXPERIENCES
por: Strelchuk, Daniela, et al.
Publicado: (2020)

T234. MEASURING PERSONAL RECOVERY IN PEOPLE WITH A PSYCHOTIC DISORDER BASED ON CHIME: A COMPARISON OF RELIABILITY AND VALIDITY PROPERTIES ON THREE VALIDATED MEASURES
por: Sjoerd Vogel, Jelle, et al.
Publicado: (2020)

T158. NO ALTERATION OF PITUTARY VOLUME IN PATIENTS WITH FIRST-EPISODE SCHIZPHRENIA BUT A TREND OF ENLARGEMENT IN NON-PSYCHOTIC FIRST-DEGREE RELATIVES
por: Chu, Min-yi, et al.
Publicado: (2020)

T104. PSYCHOTIC-LIKE EXPERIENCES AND PROBLEMATIC GAMING BEHAVIOR IN ONLINE GAME FORUMS
por: Santesteban-Echarri, Olga, et al.
Publicado: (2020)

T36. NEURAL CHANGES FOLLOWING A BODY-ORIENTED RESILIENCE THERAPY WITH ELEMENTS OF KICKBOXING FOR INDIVIDUALS WITH A PSYCHOTIC DISORDER: A RANDOMIZED CONTROLLED TRIAL
por: van der Stouwe, Elisabeth, et al.
Publicado: (2020)

T187. ATHENS MULTIFAMILY THERAPY PROJECT THE ATHENS MULTIFAMILY THERAPY PROJECT (A- MFTP) PROVIDES SYSTEMIC MULTIFAMILY GROUP THERAPY TO YOUTHS WHO EXPERIENCED A FIRST PSYCHOTIC EPISODE (FEP) AND THEIR FAMILIES
por: Selakovic, Mirjana, et al.
Publicado: (2020)

T215. THE ANTIPSYCHOTIC ACTION OF HALOPERIDOL IN PSYCHOTIC-LIKE RATS REQUIRES PRESYNAPTIC VESICULAR ACCUMULATION
por: Müller, Christian, et al.
Publicado: (2020)

T124. ATOPY INCREASES RISK OF PSYCHOTIC EXPERIENCES: A LARGE POPULATION-BASED STUDY
Publicado: (2020)

T110. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA
por: Lee, Euijin, et al.
Publicado: (2020)

T101. ABERRANT SALIENCE PREDICTS PSYCHOTIC-LIKE AND DISORGANIZED SYMPTOMS IN DAILY LIFE: AN EXPERIENCE SAMPLING STUDY
Publicado: (2020)

T5. STRESS SENSITIZATION AS THE UNDERLYING MECHANISM LINKING CHILDHOOD TRAUMA AND PSYCHOTIC-LIKE SYMPTOMS IN NONCLINICAL YOUNG ADULTS
por: Torrecilla, Pilar, et al.
Publicado: (2020)

T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES
por: Mongan, David, et al.
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

T29. CHILDHOOD PSYCHOPATHOLOGY ACROSS 12 YEARS PREDICTS ADULT PSYCHOTIC-LIKE EXPERIENCES: A PARALLEL TWO-PART PIECEWISE LATENT GROWTH CURVE MODEL
por: Ka-Yee Wong, Keri, et al.
Publicado: (2020)

T38. POSTER PRESENTATION: HAMLETT: HANDLING ANTIPSYCHOTIC MEDICATION, A LONGTERM EVALUATION OF TARGETED TREATMENT A PRAGMATIC SINGLE-BLIND RANDOMISED CONTROLLED TRIAL OF CONTINUATION VERSUS DISCONTINUATION OF PSYCHOTIC MEDICATION
por: van‘t Hag, Erna
Publicado: (2020)

905 Utility of COVID-19 universal screening protocol for pregnant patients: review of maternal characteristics and outcomes
por: Crosland, Adam, et al.
Publicado: (2021)

T27. COGNITIVE RESERVE IN CHILD AND ADOLESCENT OFFSPRING OF PATIENTS DIANOSED WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
por: De la Serna, Elena, et al.
Publicado: (2020)

T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT
por: Scheffler, Frederika, et al.
Publicado: (2020)

T168. MACULAR THINNING IN FEMALE PATIENTS WITH PSYCHOSIS SPECTRUM DISORDERS: PRELIMINARY OPTICAL COHERENCE TOMOGRAPHY FINDINGS
por: Jerotic, Stefan, et al.
Publicado: (2020)

T94. VIRTUAL REALITY STRESS REDUCTION FOR PATIENTS WITH PSYCHIATRIC DISORDERS: CROSS-OVER RANDOMIZED CONTROLLED TRIAL
por: Veling, Wim, et al.
Publicado: (2020)

T190. COMPARABILITY OF PATIENT AND STUDY CHARACTERISTICS IN RANDOMIZED CONTROLLED TRIALS ON PHARMACOTHERAPY AND PSYCHOTHERAPY FOR POSITIVE SYMPTOMS OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Publicado: (2020)

T173. POLYGENETIC RISK SCORES FOR MAJOR PSYCHIATRIC DISORDERS AMONG SCHIZOPHRENIA PATIENTS, THEIR FIRST-DEGREE RELATIVES AND HEALTHY SUBJECTS
por: Ohi, Kazutaka, et al.
Publicado: (2020)

T226. PSYCHOMETRIC INVESTIGATION OF SELF-REPORTED THOUGHT DISORDER IN NON-CLINICAL SAMPLES
por: Sumner, Philip, et al.
Publicado: (2020)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

Severe COVID-19 in pregnancy has a distinct metabolomic profile which defines clinical outcomes
por: Altendahl, Marie, et al.
Publicado: (2022)

T194. SUBJECTIVE ANOMALIES OF IMAGINATION AGGREGATE IN SCHIZOPHRENIA-SPECTRUM DISORDERS AND ARE ASSOCIATED WITH DISORDERS OF BASIC SELF
por: Rosén Rasmussen, Andreas, et al.
Publicado: (2020)

822 Characteristics of the COVID-19 outbreak in a midwest pregnant population
por: Forde, Braxton, et al.
Publicado: (2021)

T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
por: Lähteenvuo, Markku, et al.
Publicado: (2020)

T153. THE ECONOMIC BURDEN OF MENTAL DISORDERS: A SYSTEMATIC REVIEW
por: Christensen, Maria, et al.
Publicado: (2020)

T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS
por: Hoprekstad, Gunnhild, et al.
Publicado: (2020)

T26. VISUO-TACTILE TRANSFER AND AUDIO-VISUAL INTEGRATION IMPAIRMENT AS A NEW VULNERABILITY MARKER IN CHILDREN-AT-RISK OF SCHIZOPHRENIA, BIPOLAR DISORDER OR RECURRENT DEPRESSIVE DISORDER
por: Roy, Martin, et al.
Publicado: (2020)

T1. CLINICAL PROFILE AND PREVALENCE OF POSTTRAUMATIC STRESS SYMPTOMS AMONG SERVICE-USERS REFERRED FOR PSYCHOLOGICAL FOLLOW-UP: UTILITY OF ASSESSING SYMPTOMS SEVERITY RANGE
por: Penney, Danielle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39n2r75q9da35tbfbptqfas437